A Phase 1, Two-part, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR206 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs SPR-206 (Primary)
- Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Adverse reactions; First in man
- Sponsors Spero Therapeutics
- 04 Nov 2019 According to an Spero Therapeutics media release, top-line data from the study is expected by year-end 2019.
- 24 Jul 2019 Planned number of patients changed from 108 to 104.
- 24 Jul 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2019.